Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations

Table 1 Baseline characteristics reported by the participants (n = 1050)

Questionnaire items	mean ± SD; median (IQR) or n(%)
Demographic characteristics
Age (n = 796)	41.9 ± 12.4; 40.0 (32.0–51.0)
Gender
Female	522/798 (65.4)
Male	276/798 (34.6)
Language
Italian	213 (20.3)
Finnish	146 (13.9)
Portuguese	146 (13.9)
Slovenian	128 (12.2)
Spanish	120 (11.4)
Greek	102 (9.7)
English	83 (7.9)
German	57 (5.4)
French	55 (5.3)
IBD characteristics and treatments
Diagnosis
Crohn’s disease	427/798 (53.5)
Ulcerative colitis	355/798 (44.5)
No gastrointestinal condition	5/798 (0.6)
Other gastrointestinal condition	11/798 (1.4)
Crohn’s disease duration (yr)	13.6 ± 10.6; 11 (5–20)
Ulcerative colitis duration (yr)	7.52 ± 9.12; 4 (1–8)
Self-perceived disease activity
Inactive	155/770 (20.1)
Mildly active	261/770 (33.9)
Moderately active	251/770 (32.6)
Severely active	76/770 (9.9)
Not sure	27/770 (3.5)
Self-perceived disease severity since diagnosis
Mild	173/768 (22.5)
Moderate	360/768 (46.9)
Severe	201/768 (26.2)
Not sure	34/768 (4.4)
Intestinal surgery	230/798 (28.8)
Type of surgery
Partial colectomy	41/798 (5.1)
Full colectomy	29/798 (3.6)
Small-bowel resection	48/798 (6.0)
Ileocaecal resection	94/798 (11.8)
Other	79/798 (9.9)
Current IBD-related medications
Antibiotics	41/798 (5.1)
Oral aminosalicylate	318/798 (39.8)
Topical aminosalicylate	91/798 (11.4)
Topical steroid	47/798 (5.9)
Systemic steroid	78/798 (9.8)
Budesonide	28/798 (3.5)
Immunomodulator	213/798 (26.7)
Anti-TNF	225/798 (28.2)
Combination of anti-TNF and immunomodulator	69/798 (8.6)
Anti-integrin	51/798 (6.4)
Tofacitinib	6/798 (0.8)
Ustekinumab	28/798 (3.5)
None	76/798 (9.5)
Other	135/798 (16.9)
Duration of current medical therapy (yr)
< 1	240/765 (31.4)
1-5	262/765 (34.2)
> 5	263/765 (34.4)
Concomitant non-IBD drug treatment
Yes	282/767 (63.2)
No	485/767 (36.8)

The survey had a hierarchical structure, meaning that only patients who answered to certain items could answer to other following questions. For this reason, the denominator for several questions is different. In some cases, the patient did not answer and this can result in a missing value. We have transparently declared in our tables the denominator we have used to calculate the proportion of patients giving certain answers. IBD: Inflammatory bowel diseases; IQR: Interquartile ranges.